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Expanding targets of  
vitamin D receptor activation: 
downregulation of several RAS 
components in the kidney
Ilkka H. Pörsti1
Vitamin D receptor (VDR) activation has a beneficial influence on the 
progression of experimental renal insufficiency, and reduced renal 
tissue renin expression may play a role in this process. Freundlich 
and co-workers now report that VDR activation also suppresses the 
expression of angiotensinogen, angiotensin II type 1 receptor, and renin 
receptor in the kidneys of 5/6 nephrectomized rats, effects associated 
with reduced blood pressure and urinary protein excretion and with 
alleviated renal tissue damage.
Kidney International (2008) 74, 1371–1373. doi:10.1038/ki.2008.424
Vitamin D: regulation of plasma calcium 
and phosphate, and a lot more
Vitamin D is not only involved in the regu-
lation of calcium homeostasis and bone 
mineralization via vitamin D receptor 
(VDR) activation but also has antiprolif-
erative, pro-differentiation, and immuno-
modulatory activities. The VDR is found 
ubiquitously throughout the body and has 
been well characterized in the parathyroid 
cells, osteoblasts, and intestinal enterocytes. 
However, the function of the VDR in many 
other tissues has not been established. In 
addition to the treatment of secondary 
hyperparathyroidism, the potential value 
of vitamin D and its metabolites has been 
of considerable interest in many other 
diseases, including osteoporosis, cancer, 
autoimmune diseases, and infectious dis-
eases. The vitamin D endocrine system also 
participates in the regulation of blood pres-
sure, volume homeostasis, cardiac function, 
and protection of renal cellular integrity 
(reviewed by Holick1 and Andress2).
It seems clear that the altered vitamin D 
status contributes to the cardiovascular 
pathology in chronic renal insufficiency, 
with associated changes in the function 
of various tissues, including vascular 
smooth muscle and the heart. In hemo-
dialysis patients, the treatment of second-
ary hyperparathyroidism by calcitriol 
has been suggested to induce regression 
of myocardial hypertrophy. A reduced 
calcitriol level may also contribute to the 
enhanced fibrogenesis in chronic renal 
insufficiency.3 The nonclassical mecha-
nisms of VDR activation may play an 
important role in the alleged improved 
survival of patients with renal failure 
treated with calcitriol or its analogues.4
The local intrarenal renin–angiotensin 
system (RAS) is an important determi-
nant of kidney tissue injury, inflamma-
tion, and progression of renal disease, and 
inhibition of the actions of the RAS can 
preserve renal function in chronic kidney 
disease.5 An inverse relationship between 
plasma calcitriol and renin activity was 
observed more than two decades ago in 
patients with essential hypertension.6 In 
concert with these seminal findings, mice 
lacking the VDR and mice with inhibited 
calcitriol synthesis showed hypertension, 
increased renal expression of renin, 
elevated angiotensin II (Ang II) levels, 
and cardiac hypertrophy.7 Today a widely 
accepted concept is that VDR activation 
is a negative endocrine regulator of renin 
expression in the kidney independent of 
calcium metabolism.
Vitamin D receptor activation  
and the renal renin–angiotensin system
VDR activation regulates the expres-
sion of a large number of genes in the 
kidney.8 The results of Freundlich and 
co-workers9 (this issue) indicate that the 
effects of VDR activation on RAS compo-
nents are not limited to reduced expres-
sion of renin. In 5/6 nephrectomized rats, 
treatment with pari calcitol was associ-
ated with suppression of several RAS 
components in the kidney: renin, renin 
receptor, angiotensinogen, and Ang II 
type 1 receptor (AT1R). Paricalcitol 
treatment also reduced blood pressure, 
proteinuria, glomerular sclerosis, and 
tubulointerstitial damage, thus retarding 
the progression of renal tissue damage, 
with associated reduced expression of 
vascular endothelial growth factor and 
transforming growth factor-β (TGF-β). 
Decreased TGF-β expression following 
VDR activation appears to be an impor-
tant mechanism to reduce fibrogenesis 
in the kidney. It is of note that calcitriol 
can inhibit matrix-producing interstitial 
myofibroblast activation via upregulation 
of antifibrotic hepatocyte growth factor 
gene expression, and that VDR activation 
may exert renoprotective activity by sup-
pressing inflammatory-cell infiltration 
and inhibiting nuclear factor-κB activa-
tion. The lack of VDR activation may thus 
also result in increased susceptibility to 
inflammatory stimulation.2,4
The findings of Freundlich and co-
workers9 are supported by recent obser-
vations in mice made deficient in calcitriol 
by targeted ablation of the 1α-(OH)
ase gene, which showed that exogenous 
calcitriol not only normalized serum 
calcium and phosphorus levels but also 
normalized blood pressure, cardiac 
structure–function, and RAS components, 
as evaluated by measurements of plasma 
renin activity, plasma Ang II, and aldos-
terone concentrations, as well as renin and 
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higher, and the same holds true for the 
number of RAS regulators. VDR activa-
tion has established or newly suggested 
effects on renin, angiotensinogen, Ang II, 
AT1R, and renin receptor, but the influ-
ences remain unknown on Ang II type 2 
and type 4 receptors (AT2R and AT4R), 
angiotensin-converting enzyme 2, and the 
angiotensin(1–7) receptor mas oncogene, 
which contribute to cardiovascular func-
tion and growth.5 Via reduction of renin 
and angiotensinogen, VDR activation also 
has the potential to influence the levels of 
angiotensin(1–7) and the novel angiotensin 
precursor angiotensin(1–12), formed from 
angiotensinogen via non-renin mecha-
nisms. VDR can cross-talk with diverse 
cellular signals by forming complexes with 
a wide variety of transcription factors,2 and 
the influence of VDR activation on several 
RAS components remains to be elucidated 
(Figure 1).
More active treatment with vitamin D 
receptor activators — or combination 
treatment?
The synergism between VDR activa-
tion and RAS inhibition carries interest-
ing therapeutic potential. Low vitamin 
D status is common not only in patients 
with chronic kidney disease but also in 
the general population.1 The findings on 
RAS favor a more active treatment with 
VDR activators in chronic kidney disease 
patients. However, the use of VDR ana-
logues appears to suppress endogenous 
calcitriol levels in plasma, but what hap-
pens in the long term at the tissue level is 
unknown. This may be important, as cal-
citriol and activated vitamin D analogues 
may differ in their ancillary effects, and 
some of the ancillary effects may favor the 
analogues, but others may favor calcitriol.4 
The 1α-(OH)ase is widely distributed, and 
local calcitriol synthesis from calcidiol may 
play an important role in regulation of vari-
ous cellular processes in different tissues.1,2 
An unanswered question is whether there 
is a need to ensure normal concentrations 
of calcidiol — or calcitriol — in addition to 
the use of a VDR analogue.
Can we clinically influence RAS com-
ponents in vivo in humans with VDR acti-
vators without side effects; does this have 
an influence on the progression of renal 
disease; and what doses are needed? The 
remains that VDR stimulation especially 
affected the genes activated following 
surgery. Moreover, if the study protocol 
had included a longer disease progression 
period following renal mass reduction, 
the outcome might not have been quite as 
favorable. However, inhibition of calcitriol 
synthesis in normal mice increases renin 
expression, whereas calcitriol injection 
results in renin suppression.7 The reports 
of activated RAS in VDR knockout mice, 
and in mice with targeted ablation of the 
1α-(OH)ase gene, indicate that renal abla-
tion is not a prerequisite for VDR activa-
tion to influence RAS components.10,11
The cell types responsible for the dif-
ferences in RAS component expression 
after VDR activation remain unknown.9 
Following renal mass reduction there is 
suppressed juxtaglomerular renin syn-
thesis but de novo synthesis of renin in 
the tubular epithelium. In contrast to the 
normal increase in juxtaglomerular renin, 
tubular renin expression is reduced with 
angiotensin-converting enzyme inhibi-
tion.13 Renal AT1R expression in 5/6 
nephrectomized rats is also increased 
in the interstitial component in areas 
of tissue injury, whereas in normal rats 
the expression is predominantly tubular. 
VDR activation with paricalcitol can thus 
be argued to have influenced the patho-
logical expression of RAS components 
following 5/6 nephrectomy.
The renin–angiotensin system:  
increasing complexity
The RAS is becoming ever more complex 
and the number of its known components 
angiotensinogen mRNA levels and renin 
protein levels in the kidney.10 Another 
interesting report, by Zhang and co-
workers, recently showed that diabetic 
VDR knockout mice develop more severe 
albuminuria and glomerulosclerosis than 
wild-type control mice, and that increased 
expression of renin, angiotensinogen, 
TGF-β, and connective tissue growth 
factor accompanied more severe renal 
injury.11 Their results indicate that 
receptor-mediated vitamin D actions are 
renoprotective in experimental diabetic 
nephropathy and that higher activation 
of the intrarenal RAS is the key factor to 
induce more severe diabetic nephropathy 
in VDR knockout mice.
The inhibition of the RAS by medical 
compounds is often referred to as being 
renoprotective, but despite active drug 
treatment, the course of many renal dis-
eases can only be slowed down, not pre-
vented. Therefore, all additional treatment 
modalities are welcome, and VDR activa-
tion may be one such approach. Supporting 
a synergistic action between VDR activa-
tion and pharmacological RAS blockade, 
paricalcitol treatment was found to retard 
the progression of experimental renal 
insufficiency via an effect on the TGF-β 
signaling pathway, and this effect was 
amplified with simultaneous angiotensin-
converting enzyme inhibition.12
Some remarks on study limitations
The experiment design did not include 
a sham-operated group treated with 
paricalcitol.9 As the treatment already 
started 4 days after surgery, the possibility 
Figure 1 | Established or newly suggested effects of vitamin D receptor activation on the 
components of the renin–angiotensin system.
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ongoing randomized clinical trials on the 
effects of VDR activation on renal failure-
induced cardiac mortality and the progres-
sion of albuminuria (PRIMO and VITAL) 
seem highly warranted, and we are awaiting 
the results. The present results of Freund-
lich et al.9 show that the expanding targets 
of VDR activation include downregulation 
of multiple RAS components.
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Regulation of the Na+-Cl– 
cotransporter by dietary NaCl:  
a role for WNKs, SPAK, OSR1,  
and aldosterone
Volker Vallon1,2,3
This Commentary aims to integrate or interrelate the available data with 
the current study by Chiga and co-workers, which defines an important 
influence of aldosterone in the phosphorylation and thus activation of 
the Na+-Cl– cotransporter (NCC) in response to changes in NaCl intake 
and implicates the involvement of SPAK/OSR1 kinases and WNKs.
Kidney International (2008) 74, 1373–1375. doi:10.1038/ki.2008.477
An impaired ability of the kidney to 
excrete NaCl plays a critical pathophysi-
ological role for a long-term increase in 
blood pressure. The aldosterone-sensi-
tive distal nephron is of primary impor-
tance in the regulation of renal NaCl 
excretion and thus body NaCl home-
ostasis. The stimulatory effect of aldos-
terone on the epithelial sodium channel 
(ENaC) is well known and primarily 
localized to the late distal convoluted 
tubule (DCT) and connecting tubule. 
Less appreciated is the regulation of the 
Na+-Cl– cotransporter (NCC) in the 
DCT by aldosterone and other regula-
tors. Moreover, whereas much has been 
learned about the molecular pathways 
involved in the regulation of ENaC, 
still relatively little is known about the 
determinants of NCC activity. The study 
by Chiga and co-workers1 (this issue) 
provides new in vivo evidence in this 
regard, as they indicate an important 
role of aldosterone in the regulation of 
NCC phosphorylation by dietary salt 
intake. Moreover, evidence is provided 
that the signaling cascade involves with-
no-lysine kinase (WNK) and the mam-
malian STE20 (sterile 20)-like kinases 
SPAK (STE20/SPS1-related proline/
alanine-rich kinase) and OSR1 (oxida-
tive stress-responsive kinase-1).
SPAK and OSR1 were discovered 
through their ability to interact with, 
phosphorylate, and stimulate the activ-
ity of the Na+-K+-2Cl– cotransporter 
(NKCC1), a member of a superfamily of 
electroneutral cation-coupled chloride 
cotransporters (SLC12) (reviewed by 
Delpire and Gagnon2). The Na+-driven 
members of this superfamily include 
NKCC1 and NKCC2, as well as NCC. 
Fragments of these cotransporters con-
taining a cluster of conserved threonine 
residues are phosphorylated in vitro by 
the SPAK/OSR1 kinases. The SPAK and 
OSR1 enzymes themselves are phospho-
rylated and activated by the WNK1 and 
WNK4 protein kinases (reviewed by 
Delpire and Gagnon2). These findings 
suggest that a signaling cascade includ-
ing WNK1, WNK4, and SPAK/OSR1 
could be involved in the regulation of 
the Na+-driven members of the SLC12 
superfamily, including NCC.
WNK1 and WNK4 are mutated in 
patients with pseudohypoaldosteronism 
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